Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

• Status: Recruiting
• Trial end date: 2025-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• Pathology confirmed nasopharyngeal squamous cell carcinoma.

• Aged 18 to 70 years old;

• Stage II-III (T1N1M0，T2-3N0-1M0) diseases according to 8th AJCC Staging and the shortest diameter of the largest lymph node involved is no more than 3cm;

• KPS≥70;

• Have measurable lesions on CT/MRI before treatment;

• Treatment for the first time;

• At least 6 months lifetime was expected;

• Adequate laboratory indexes, defined as follows: Hemoglobin > 120g/L, WBC > 4.0x10*9/L, Plt > 100x10*9/L < 2, all indexes of liver and kidney function ≤ 1.25 times of the institutional upper limit of normal value, no hearing loss;

• Can understand and sign the consent

• Have follow up condition

Exclusion Criteria:

• Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ)

• Previously treatment for cancer

• Pregnant or breeding woman, female without contraception

• Enrolling in other drug trials

• Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular disease, ulceration disease, mental disease and uncontrolled diabetes

• Without follow up